224 related articles for article (PubMed ID: 30802029)
1. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
Ning Q; Liu YF; Ye PJ; Gao P; Li ZP; Tang SY; He DX; Tang SS; Wei H; Yu CY
ACS Appl Mater Interfaces; 2019 Mar; 11(11):10578-10588. PubMed ID: 30802029
[TBL] [Abstract][Full Text] [Related]
2. Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy
Xiang Y; Huang W; Huang C; Long J; Zhou Y; Liu Y; Tang S; He DX; Tan XW; Wei H; Yu CY
Mol Pharm; 2020 Sep; 17(9):3223-3235. PubMed ID: 32658485
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy.
Huang C; Li NM; Gao P; Yang S; Ning Q; Huang W; Li ZP; Ye PJ; Xiang L; He DX; Tan XW; Yu CY
Drug Deliv; 2017 Nov; 24(1):459-466. PubMed ID: 28219253
[TBL] [Abstract][Full Text] [Related]
4. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
Cheng MR; Li Q; Wan T; He B; Han J; Chen HX; Yang FX; Wang W; Xu HZ; Ye T; Zha BB
World J Gastroenterol; 2012 Nov; 18(42):6076-87. PubMed ID: 23155336
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
Cheng M; Ma D; Zhi K; Liu B; Zhu W
Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
[TBL] [Abstract][Full Text] [Related]
6. Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma.
Ni W; Li Z; Liu Z; Ji Y; Wu L; Sun S; Jian X; Gao X
J Pharm Sci; 2019 Mar; 108(3):1284-1295. PubMed ID: 30395829
[TBL] [Abstract][Full Text] [Related]
7. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
Cheng M; He B; Wan T; Zhu W; Han J; Zha B; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
PLoS One; 2012; 7(10):e47115. PubMed ID: 23077553
[TBL] [Abstract][Full Text] [Related]
8. Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.
Chen S; Ouyang H; He D; Liu D; Wang X; Chen H; Pan W; Li Q; Xie W; Yu C
Curr Pharm Des; 2022; 28(25):2113-2125. PubMed ID: 35524673
[TBL] [Abstract][Full Text] [Related]
9. Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
Varshosaz J; Fard MM; Mirian M; Hassanzadeh F
Anticancer Agents Med Chem; 2020; 20(3):346-358. PubMed ID: 31566137
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
11. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy.
Qu CY; Zhou M; Chen YW; Chen MM; Shen F; Xu LM
Int J Nanomedicine; 2015; 10():3911-20. PubMed ID: 26089667
[TBL] [Abstract][Full Text] [Related]
12. Preparation, Synergism, and Biocompatibility of in situ Liquid Crystals Loaded with Sinomenine and 5-Fluorouracil for Treatment of Liver Cancer.
Cao J; Huang J; Gui S; Chu X
Int J Nanomedicine; 2021; 16():3725-3739. PubMed ID: 34103913
[TBL] [Abstract][Full Text] [Related]
13. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
14. MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.
Shi L; Wu L; Chen Z; Yang J; Chen X; Yu F; Zheng F; Lin X
Cell Physiol Biochem; 2015; 35(6):2333-48. PubMed ID: 25896253
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.
Hu Z; Lv G; Li Y; Li E; Li H; Zhou Q; Yang B; Cao W
J Exp Clin Cancer Res; 2016 Apr; 35():71. PubMed ID: 27102814
[TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.
Liao B; Liang H; Chen J; Liu Q; Zhang B; Chen X
Tumour Biol; 2015 Dec; 36(12):9347-56. PubMed ID: 26108995
[TBL] [Abstract][Full Text] [Related]
17. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
Cheng M; Liu Z; Wan T; He B; Zha B; Han J; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
Cancer Biol Ther; 2012 Dec; 13(14):1407-16. PubMed ID: 22954702
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
19. Facile fabrication of a novel hybrid nanoparticles by self-assembling based on pectin-doxorubicin conjugates for hepatocellular carcinoma therapy.
Ye PJ; Huang C; Yang S; Gao P; Li ZP; Tang SY; Xiang Y; Liu YF; Chen YP; He DX; Yu CY
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S661-S670. PubMed ID: 30307317
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.
Cheng M; Gao X; Wang Y; Chen H; He B; Xu H; Li Y; Han J; Zhang Z
Mar Drugs; 2013 Sep; 11(9):3517-36. PubMed ID: 24048270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
